IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (currently amended) A pharmaceutical preparation comprising, as an active ingredient, a Sendai virus envelope vector having a chemotherapeutic agent incorporated therein.

2. (original) The pharmaceutical preparation according to claim 1, wherein the chemotherapeutic agent is a cancerocidal agent, an anticancer agent, or an antitumor agent.

3. (currently amended) A pharmaceutical preparation comprising, as an active ingredient, a Sendai virus envelope vector having a chemotherapeutic agent incorporated therein: ~~The pharmaceutical preparation according to claim 1,~~ wherein the chemotherapeutic agent is at least one member selected from the group consisting of bleomycin and derivatives thereof, anthraquinone-based cancerocidal agents, mitomycin and derivatives thereof, actinomycin and derivatives thereof, taxane derivatives, camptothecin and derivatives thereof, cisplatin and derivatives thereof, staurosporine and derivatives thereof, vincristine, streptozotocin, 5-fluorouracil (5-FU) and derivatives thereof, viralbicin, dolastatin, and pharmacologically acceptable salts thereof.

4. (currently amended) The pharmaceutical preparation according to claim [[1]] 3, wherein the chemotherapeutic agent is ~~bleomycin and derivatives thereof are~~ bleomycin or a pharmacologically acceptable salt thereof or peplomycin or a pharmacologically acceptable salt ~~salts~~ thereof.

Claims 5-7 (canceled)

8. (currently amended) The pharmaceutical preparation according to claim [[1]] 3, wherein the chemotherapeutic agent is at least one member selected from the group consisting of bleomycin hydrochloride, bleomycin sulfate and peplomycin sulfate~~, and the virus is Sendai virus~~.

9. (previously presented) The pharmaceutical preparation according to claim 1, which is an injection.

10. (currently amended) A method of making a pharmaceutical preparation, which comprises: ~~The pharmaceutical preparation according to claim 1, wherein a surfactant is used in the step of~~ incorporating [[the]] a chemotherapeutic agent into [[the]] a Sendai virus envelope vector using a surfactant.

11. (currently amended) The method of making a pharmaceutical preparation according to claim 10, wherein the surfactant is one member selected from the group consisting of Triton X100, deoxycholic acid and salts thereof, and cholic acid and salts thereof.

12. (currently amended) A method of treating a solid cancer, which comprises: administering to a patient a pharmaceutical preparation comprising, as an active ingredient, a Sendai virus envelope vector having a chemotherapeutic agent for the solid cancer incorporated therein. ~~The pharmaceutical preparation according to claim 1, which is a therapeutic agent for solid cancer~~.

13. (currently amended) The method of treating a solid cancer ~~pharmaceutical preparation~~ according to claim [[1]] 12, wherein the solid tumor is one member selected from the group consisting of lung cancer, breast cancer, digestive organ cancer, head and neck cancer, gynecologic cancer, urologic cancers, soft tissue and bone sarcoma, malignant lymphoma and cancer of unknown primary.

14. (currently amended) The method of treating a solid cancer ~~pharmaceutical preparation~~ according to claim [[13]] 12, wherein the solid tumor ~~digestive organ cancer~~ is one member selected from the group consisting of stomach cancer, colon cancer and esophagus cancer.

15. (currently amended) The method of treating a solid cancer ~~pharmaceutical preparation~~ according to claim [[13]] 12, wherein the solid tumor ~~head and neck cancer~~ is one member selected from the group consisting of upper jaw cancer, tongue cancer, lip cancer, pharynx cancer, larynx cancer and oral cavity cancer.

16. (currently amended) The method of treating a solid cancer ~~pharmaceutical preparation~~ according to claim [[13]] 12, wherein the solid tumor ~~gynecologic cancer~~ is one member selected from the group consisting of uterus cancer, ovarian cancer and uterine cervical cancer.

17. (currently amended) The method of treating a solid cancer ~~pharmaceutical preparation~~ according to claim [[13]] 12, wherein the solid tumor ~~urologic cancers~~ is prostate cancer.

18. (currently amended) A method of treating a cancer, which comprises using a chemotherapeutic agent-incorporated Sendai virus envelope vector in combination with a platinum complex and/or an antimetabolite.

19. (original) The method of treating a cancer according to claim 18, wherein the platinum complex is one member selected from the group consisting of cisplatin, carboplatin, Parapratin and nedaplatin.

20. (original) The method of treating a cancer according to claim 18, wherein the antimetabolite is one member selected from the group consisting of 6-mercaptopurine riboside, enocitabin, gemcitabine HCl, carmofur, cytarabine, cytarabine ocfosfate,

tegafur, tegafur-uracil, tegafur-gimeracil-oteracil-potassium, doxifluridine, hydroxycarbamide, fluorouracil, methotrexate, mercaptopurine and fludarabine phosphate.

21. (currently amended) A method of treating a cancer, which comprises using a chemotherapeutic agent-incorporated Sendai virus envelope vector in combination with cisplatin and/or fluorouracil.

22. (currently amended) [[A]] The method of treating a cancer according to claim 21, which comprises using a chemotherapeutic agent-incorporated Sendai virus envelope vector in combination with cisplatin and/or fluorouracil, and subsequent irradiation ~~with radiations~~.

23. (currently amended) [[A]] The method of treating a cancer according to claim 21, which comprises using a bleomycin- or its pharmacologically acceptable salt-incorporated Sendai virus envelope vector in combination with cisplatin and/or fluorouracil, and subsequent irradiation ~~with radiations~~.

24. (new) The method of treating a solid cancer according to claim 12, wherein the pharmaceutical preparation is administered by an injection.

25. (new) The method of treating a solid cancer according to claim 12, wherein the chemotherapeutic agent is at least one member selected from the group consisting of bleomycin and derivatives thereof, anthraquinone-based cancerocidal agents, mitomycin and derivatives thereof, actinomycin and derivatives thereof, taxane derivatives, camptothecin and derivatives thereof, cisplatin and derivatives thereof, staurosporine and derivatives thereof, vincristine, streptozotocin, 5-fluorouracil (5-FU) and derivatives thereof, viralbicin, dolastatin, and pharmacologically acceptable salts thereof.

26. (new) The method of treating a solid cancer according to claim 12, wherein the chemotherapeutic agent is at least one member selected from the group consisting of bleomycin hydrochloride, bleomycin sulfate and peplomycin sulfate.